1048962-94-2

Basic information

• Product Name: 1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol
• Synonyms: 1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol;trans-Methyl 5-hydroxytetrahydro-2H-pyran-3-carboxylate
• CAS NO: 1048962-94-2
• Molecular Formula: C7H12O4
• Molecular Weight: 160.16778
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1048962-94-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 252℃
• Flash Point: 101℃
• Appearance: /
• Density: 1.212
• PKA: 14.09±0.40(Predicted)
• CAS DataBase Reference: 1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol(1048962-94-2)
• EPA Substance Registry System: 1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol(1048962-94-2)

Safety Data

• Hazardous Substances Data: 1048962-94-2(Hazardous Substances Data)

Usage

Description

1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol is a tetrahydropyran derivative, a type of organic compound that is characterized by a six-membered oxygen-containing ring structure. It is known for its potential applications in the pharmaceutical industry due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol is used as an intermediate in the synthesis of pharmaceutical compounds for the prevention or delay of the progression of Alzheimer's disease, malaria, and HIV infections. Its unique structure allows it to be a key component in the development of drugs targeting these conditions.
In Alzheimer's Disease Prevention:
1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol is used as a building block in the creation of drugs that aim to prevent or slow down the progression of Alzheimer's disease. Its chemical properties enable it to be incorporated into molecules that can target the underlying causes of the disease, such as amyloid-beta plaque formation and neurofibrillary tangle formation.
In Malaria Treatment:
1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol is used as a component in the development of antimalarial drugs. Its structure allows it to be part of molecules that can effectively target the Plasmodium parasites responsible for malaria, potentially leading to more effective treatments for this life-threatening disease.
In HIV Infection Management:
1,5-Anhydro-2,3-dideoxy-2-(methoxycarbonyl)-threopentitol is used as a key intermediate in the synthesis of antiretroviral drugs. Its unique properties make it suitable for the development of medications that can target the HIV virus, helping to manage the infection and improve the quality of life for those affected by the disease.

Upstream product

• 186581-53-3 diazomethane 
• 1048962-91-9 (±)-cis-methyl 5-hydroxytetrahydro-2H-pyran-3-carboxylate 
• 127956-19-8 methyl 5-oxotetrahydro-2H-pyran-3-carboxylate 
• 127956-18-7 methyl 3-(iodomethyl)-4-(phenylimino)tetrahydrofuran-3-carboxylate 
• 127956-17-6 methyl 4-(phenylamino)-2,5-dihydrofuran-3-carboxylate 
• 57595-23-0 methyl 4-oxotetrahydrofuran-3-carboxylate 
• 61363-56-2 2H-pyran-3,5(4H,6H)-dione 

Relevant articles and documents

ISOXAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Key intermediate of 5-oxo-tetrahydropyrane-3-carboxylate and preparation method of key intermediate

The invention discloses a key intermediate of 5-oxo-tetrahydropyrane-3-carboxylate and a preparation method of the key intermediate. The preparation method of the key intermediate comprises the following steps: carrying out halogenating reaction by taking 2H-pyran-3,5(4H, 6H)-diketone (compound II) as a raw material to obtain a compound III; carrying out reduction reaction on the compound III to obtain a compound IV; carrying out halogen carbonyl insertion reaction on the compound IV to obtain a compound V; carrying out reduction on double bonds in a structure of the compound V to obtain a compound VI; and carrying out oxidation of hydroxy on the compound VI to obtain carbonyl and 5-oxo-tetrahydropyrane-3-carboxylate (compound I).

5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION

Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is -CH2-; R1 is a mono- to tetrasubstituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl- C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n = 0, 1 or 2; m = 0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy- C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino, or if m = 0: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy- C1-6alkyl, hydroxy- C1-6alkyl or dialkylamino, or if m = 1: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6-alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino; have renin- inhibiting properties and can be used as medicines for the treatment of hypertension.